Tools / Targets F8: Coagulation factor VIII Factor VIII, along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa.
Drugs that act on it : 16 Approved : 13 In phases 1 to 3 : 3 Sponsors : 12 Who is on it, and how far along Every drug ChEMBL records acting on F8, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Protein or peptide 11 Other 5 Approved13 Moroctocog alfa Moroctocog alfa SponsorPfizer ModalityProtein or peptide ActionExogenous protein Open trials72 Octocog alfa Octocog alfa SponsorSanofi ModalityProtein or peptide ActionExogenous protein Open trials72 Human coagulation factor viii Human coagulation factor viii SponsorHangzhou Gensciences Biopharmaceutical Co., Ltd. ModalityOther ActionExogenous protein Open trials24 Efanesoctocog alfa Efanesoctocog alfa SponsorSanofi ModalityProtein or peptide ActionExogenous protein Open trials10 Damoctocog alfa pegol Damoctocog alfa pegol SponsorBayer ModalityProtein or peptide ActionExogenous protein Open trials5 Turoctocog alfa Turoctocog alfa SponsorNovo Nordisk ModalityProtein or peptide ActionExogenous protein Open trials2 Turoctocog alfa pegol Turoctocog alfa pegol SponsorNovo Nordisk ModalityProtein or peptide ActionExogenous protein Open trials2 Efmoroctocog alfa Efmoroctocog alfa SponsorAryoGen Pharmed Co. ModalityProtein or peptide ActionExogenous protein Open trials1 Susoctocog alfa Susoctocog alfa SponsorTakeda Pharmaceuticals USA ModalityProtein or peptide ActionExogenous protein Open trials1 Antihemophilic factor, pegylated (mw 20000) human sequence recombinant Antihemophilic factor, pegylated (mw 20000) human sequence recombinant SponsorTakeda Pharmaceuticals USA ModalityOther ActionExogenous protein Open trials0 Drotrecogin alfa (activated) Drotrecogin alfa (activated) SponsorEli Lilly ModalityProtein or peptide ActionInhibitor Open trials0 Lonoctocog alfa Lonoctocog alfa SponsorCSL ModalityProtein or peptide ActionExogenous protein Open trials0 Simoctocog alfa Simoctocog alfa SponsorOctapharma ModalityProtein or peptide ActionExogenous protein Open trials0 Phase 21 TB-402 TB-402 SponsorThromboGenics ModalityOther ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 13 of 16 act as: Coagulation factor VIII exogenous protein; the rest name their own mechanism. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 31 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without Inhibitors Moroctocog alfa, Octocog alfa Phase 3 Recruiting Pfizer Nov 9, 2026 A Study to Describe Patient REal-world FitusiRan ExpeRience Moroctocog alfa, Octocog alfa — Not yet recruiting Sanofi Oct 26, 2026 Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children Moroctocog alfa, Octocog alfa Phase 3 Recruiting Hoffmann-La Roche Sep 24, 2026 Efanesoctocog Prophylaxis Or The Optimization Of Treatment: Real-World Experience Of Taylorizing Clotting Therapy In Hemophilia A Efanesoctocog alfa, Moroctocog alfa, Octocog alfa — Not yet recruiting Nantes University Hospital Sep 21, 2026 Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study Efmoroctocog alfa, Moroctocog alfa, Octocog alfa — Not yet recruiting AryoGen Pharmed Co. Aug 28, 2026 A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A Human coagulation factor viii Phase 1 / Phase 2 Recruiting Arditus Pte Ltd Aug 26, 2026 Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®) Efanesoctocog alfa, Moroctocog alfa, Octocog alfa — Recruiting Hospices Civils de Lyon Jul 23, 2026 TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies Moroctocog alfa, Octocog alfa — Recruiting University of Texas Southwestern Medical Center Jul 9, 2026 Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment. Human coagulation factor viii, Moroctocog alfa, Octocog alfa Phase 3 Active, not recruiting Hangzhou Gensciences Biopharmaceutical Co., Ltd. Jul 6, 2026 Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment Human coagulation factor viii Phase 3 Active, not recruiting Hangzhou Gensciences Biopharmaceutical Co., Ltd. Jun 23, 2026 A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study) Efanesoctocog alfa — Recruiting Arkansas Children's Hospital Research Institute May 12, 2026 Post Approval Phase 4 Study to Learn More About How Safe Octocog Alfa is, and How Well it Works in Patients With Severe Hemophilia A in India Human coagulation factor viii — Not yet recruiting Bayer Mar 3, 2026 A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A Human coagulation factor viii Phase 3 Recruiting Hoffmann-La Roche Feb 18, 2026 A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) Human coagulation factor viii Phase 3 Recruiting Takeda Aug 19, 2025 An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Children With Hemophilia A Damoctocog alfa pegol — Recruiting Bayer Jul 28, 2025 Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy Efanesoctocog alfa Phase 4 Recruiting Sanofi Apr 24, 2025 Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa Efanesoctocog alfa Phase 4 Active, not recruiting Swedish Orphan Biovitrum Apr 23, 2025 Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients Human coagulation factor viii Phase 2 / Phase 3 Not yet recruiting Dhaka Medical College Apr 22, 2025 A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis Efanesoctocog alfa Phase 4 Active, not recruiting Swedish Orphan Biovitrum Dec 31, 2024 An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients Human coagulation factor viii Phase 3 Not yet recruiting SK Plasma Co., Ltd. Dec 18, 2024 Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa Efanesoctocog alfa Phase 3 Active, not recruiting Swedish Orphan Biovitrum Dec 4, 2024 A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan Efanesoctocog alfa — Active, not recruiting Sanofi Nov 12, 2024 A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A Susoctocog alfa — Recruiting Takeda Jun 17, 2024 A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A Damoctocog alfa pegol — Recruiting Bayer Jan 25, 2024 An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A. Damoctocog alfa pegol — Active, not recruiting Bayer Dec 8, 2022 Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively Giroctocogene fitelparvovec Phase 3 Recruiting Pfizer Oct 6, 2022 Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol Turoctocog alfa, Turoctocog alfa pegol — Enrolling by invitation Novo Nordisk A/S Dec 23, 2020 A Study Following Males With Haemophilia A on Prophylaxis With Esperoct® Turoctocog alfa, Turoctocog alfa pegol — Enrolling by invitation Novo Nordisk A/S Oct 5, 2020 Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding Damoctocog alfa pegol — Active, not recruiting Bayer Jul 8, 2020 Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults Giroctocogene fitelparvovec Phase 3 Active, not recruiting Pfizer Apr 30, 2020 Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A Damoctocog alfa pegol — Active, not recruiting Bayer Apr 30, 2019
Show all 31Diseases most associated with it Open Targets association score, 0 to 1; all associations Hemophilia A 0.91 Hemophilia A Value0.91 Open Hemophilia 0.73 Hemophilia Value0.73 Open Hemophilia B 0.69 Hemophilia B Value0.69 Open Thrombophilia, X-linked, due to factor 8 defect 0.66 Thrombophilia, X-linked, due to factor 8 defect Value0.66 Hemorrhage 0.58 Hemorrhage Value0.58 Open Immune system disorder 0.57 Immune system disorder Value0.57 Sepsis 0.57 Sepsis Value0.57 Open Severe hemophilia A 0.55 Severe hemophilia A Value0.55 Mild hemophilia A 0.52 Mild hemophilia A Value0.52 Abnormality of coagulation 0.49 Abnormality of coagulation Value0.49 Hereditary disease 0.47 Hereditary disease Value0.47 Von Willebrand disease (hereditary or acquired) 0.41 Von Willebrand disease (hereditary or acquired) Value0.41 Open Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3143 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. Gene name, function (UniProt P00451 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets